Selected research
Industry Research
Gene Therapy in CNS Disorder Industry Research Report 2026
Market perspective
The global Gene Therapy in CNS Disorder market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Gene Therapy in CNS Disorder market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Gene Therapy in CNS Disorder market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Gene Therapy in CNS Disorder market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Gene Therapy in CNS Disorder include Novartis AG, Biogen, Voyager Therapeutics, Spark Therapeutics and Bluebird Bio Inc., among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Gene Therapy in CNS Disorder market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Gene Therapy in CNS Disorder.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Gene Therapy in CNS Disorder Market by Company
Novartis AG
Biogen
Voyager Therapeutics
Spark Therapeutics
Bluebird Bio Inc.
Gene Therapy in CNS Disorder Segment by Type
Viral Gene Therapy
Non-viral Gene Therapy
Gene Therapy in CNS Disorder Segment by Application
Parkinson's Disease
Huntington's Disease
Batten Disease
Alzheimer's Disease
Gene Therapy in CNS Disorder Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gene Therapy in CNS Disorder market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gene Therapy in CNS Disorder and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gene Therapy in CNS Disorder.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Gene Therapy in CNS Disorder companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Viral Gene Therapy
- Non-viral Gene Therapy
Applications
- Parkinson's Disease
- Huntington's Disease
- Batten Disease
- Alzheimer's Disease
Companies covered
- Novartis AG
- Biogen
- Voyager Therapeutics
- Spark Therapeutics
- Bluebird Bio Inc.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Gene Therapy in CNS Disorder by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Viral Gene Therapy
- 2.2.3 Non-viral Gene Therapy
- 2.3 Gene Therapy in CNS Disorder by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Parkinson's Disease
- 2.3.3 Huntington's Disease
- 2.3.4 Batten Disease
- 2.3.5 Alzheimer's Disease
- 2.4 Assumptions and Limitations
3 Gene Therapy in CNS Disorder Breakdown Data by Type
- 3.1 Global Gene Therapy in CNS Disorder Historic Market Size by Type (2021-2026)
- 3.2 Global Gene Therapy in CNS Disorder Forecasted Market Size by Type (2027-2032)
4 Gene Therapy in CNS Disorder Breakdown Data by Application
- 4.1 Global Gene Therapy in CNS Disorder Historic Market Size by Application (2021-2026)
- 4.2 Global Gene Therapy in CNS Disorder Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Gene Therapy in CNS Disorder Market Perspective (2021-2032)
- 5.2 Global Gene Therapy in CNS Disorder Growth Trends by Region
- 5.2.1 Global Gene Therapy in CNS Disorder Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Gene Therapy in CNS Disorder Historic Market Size by Region (2021-2026)
- 5.2.3 Gene Therapy in CNS Disorder Forecasted Market Size by Region (2027-2032)
- 5.3 Gene Therapy in CNS Disorder Market Dynamics
- 5.3.1 Gene Therapy in CNS Disorder Industry Trends
- 5.3.2 Gene Therapy in CNS Disorder Market Drivers
- 5.3.3 Gene Therapy in CNS Disorder Market Challenges
- 5.3.4 Gene Therapy in CNS Disorder Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Gene Therapy in CNS Disorder Players by Revenue
- 6.1.1 Global Top Gene Therapy in CNS Disorder Players by Revenue (2021-2026)
- 6.1.2 Global Gene Therapy in CNS Disorder Revenue Market Share by Players (2021-2026)
- 6.2 Global Gene Therapy in CNS Disorder Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Gene Therapy in CNS Disorder Head Office and Area Served
- 6.4 Global Gene Therapy in CNS Disorder Players, Product Type & Application
- 6.5 Global Gene Therapy in CNS Disorder Manufacturers Established Date
- 6.6 Global Gene Therapy in CNS Disorder Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Gene Therapy in CNS Disorder Market Size (2021-2032)
- 7.2 North America Gene Therapy in CNS Disorder Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Gene Therapy in CNS Disorder Market Size by Country (2021-2026)
- 7.4 North America Gene Therapy in CNS Disorder Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Gene Therapy in CNS Disorder Market Size (2021-2032)
- 8.2 Europe Gene Therapy in CNS Disorder Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Gene Therapy in CNS Disorder Market Size by Country (2021-2026)
- 8.4 Europe Gene Therapy in CNS Disorder Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Gene Therapy in CNS Disorder Market Size (2021-2032)
- 9.2 Asia-Pacific Gene Therapy in CNS Disorder Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Gene Therapy in CNS Disorder Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Gene Therapy in CNS Disorder Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Gene Therapy in CNS Disorder Market Size (2021-2032)
- 10.2 South America Gene Therapy in CNS Disorder Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Gene Therapy in CNS Disorder Market Size by Country (2021-2026)
- 10.4 South America Gene Therapy in CNS Disorder Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Gene Therapy in CNS Disorder Market Size (2021-2032)
- 11.2 Middle East & Africa Gene Therapy in CNS Disorder Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Gene Therapy in CNS Disorder Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Gene Therapy in CNS Disorder Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Novartis AG
- 12.1.1 Novartis AG Company Information
- 12.1.2 Novartis AG Business Overview
- 12.1.3 Novartis AG Revenue in Gene Therapy in CNS Disorder Business (2021-2026)
- 12.1.4 Novartis AG Gene Therapy in CNS Disorder Product Portfolio
- 12.1.5 Novartis AG Recent Developments
- 12.2 Biogen
- 12.2.1 Biogen Company Information
- 12.2.2 Biogen Business Overview
- 12.2.3 Biogen Revenue in Gene Therapy in CNS Disorder Business (2021-2026)
- 12.2.4 Biogen Gene Therapy in CNS Disorder Product Portfolio
- 12.2.5 Biogen Recent Developments
- 12.3 Voyager Therapeutics
- 12.3.1 Voyager Therapeutics Company Information
- 12.3.2 Voyager Therapeutics Business Overview
- 12.3.3 Voyager Therapeutics Revenue in Gene Therapy in CNS Disorder Business (2021-2026)
- 12.3.4 Voyager Therapeutics Gene Therapy in CNS Disorder Product Portfolio
- 12.3.5 Voyager Therapeutics Recent Developments
- 12.4 Spark Therapeutics
- 12.4.1 Spark Therapeutics Company Information
- 12.4.2 Spark Therapeutics Business Overview
- 12.4.3 Spark Therapeutics Revenue in Gene Therapy in CNS Disorder Business (2021-2026)
- 12.4.4 Spark Therapeutics Gene Therapy in CNS Disorder Product Portfolio
- 12.4.5 Spark Therapeutics Recent Developments
- 12.5 Bluebird Bio Inc.
- 12.5.1 Bluebird Bio Inc. Company Information
- 12.5.2 Bluebird Bio Inc. Business Overview
- 12.5.3 Bluebird Bio Inc. Revenue in Gene Therapy in CNS Disorder Business (2021-2026)
- 12.5.4 Bluebird Bio Inc. Gene Therapy in CNS Disorder Product Portfolio
- 12.5.5 Bluebird Bio Inc. Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst